Viracta Therapeutics, Inc. (VIRX)

Market Cap	19.24M
Revenue (ttm)	n/a
Net Income (ttm)	-47.99M
Shares Out	39.27M
EPS (ttm)	-1.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	106,534
Open	0.510
Previous Close	0.510
Day's Range	0.480 - 0.550
52-Week Range	0.430 - 1.680
Beta	0.39
Analysts	Strong Buy
Price Target	7.20 (+1,369.39%)
Earnings Date	Aug 12, 2024

About VIRX

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: VIRX

Analyst Forecast

According to 5 analysts, the average rating for VIRX stock is "Strong Buy." The 12-month stock price forecast is $7.2, which is an increase of 1,369.39% from the latest price.

Price Target

$7.2

(1,369.39% upside)

Analyst Consensus: Strong Buy